Management of Patients with Suppressed TSH, Normal Free T4, and Thyroid Nodule on Ultrasound

Evaluation and Diagnosis

The combination of suppressed TSH with normal free T4 suggests subclinical hyperthyroidism, possibly due to an autonomous hyperfunctioning nodule, according to the American College of Endocrinology 1
A thyroid scan with technetium-99m should be performed to determine if the nodule is functioning (hot) or non-functioning (cold), as recommended by the European Society of Endocrinology 2
If the nodule is non-functioning (cold), it should be evaluated by ultrasound to determine suspicious characteristics of malignancy, following the guidelines of the American Thyroid Association 3

For hyperfunctioning (hot) nodules, therapy options include ablative therapy with radioactive iodine (I-131) or surgical removal, as suggested by the European Society of Endocrinology 2
For non-functioning (cold) nodules, fine-needle aspiration biopsy (FNAB) is recommended for solid hypoechoic nodules ≥1 cm or with suspicious characteristics, according to the American Thyroid Association 3

Patients with benign nodules should be followed up with ultrasound and thyroid function tests, as recommended by the European Society of Endocrinology 2
Patients with malignant nodules treated with ablative therapy should receive TSH suppression therapy, with a target TSH level of 0.5-2.0 mU/L for absolute indications and below 0.5 mU/L for relative indications, as suggested by the International Journal of Surgery 4
Follow-up should be performed at 3, 6, and 12 months during the first year, followed by evaluations every 6 months once TSH control is achieved, according to the International Journal of Surgery 4

Ablative therapy guided by ultrasound is an option for benign nodules causing compressive symptoms or aesthetic problems, as recommended by the International Journal of Surgery 5
Nodules with a maximum diameter ≥2 cm and gradual increase are candidates for ablative therapy, according to the International Journal of Surgery 5
In malignant nodules treated with ablative therapy, TSH suppression therapy should be implemented, as suggested by the International Journal of Surgery 6
Levotiroxine (LT4) therapy should be adjusted according to the risk of recurrence and potential adverse effects, as recommended by the European Society of Endocrinology 2

Routine suppressive therapy with levotiroxine is not recommended for benign nodules, as it may cause or worsen osteoporosis, especially in postmenopausal women, according to the American Thyroid Association 3
False negatives can occur in 5-10% of FNAB, so clinical suspicion should be maintained if other worrisome characteristics are present, as suggested by the American Thyroid Association 3
Ablative therapy is contraindicated in patients with severe bleeding tendency, severe cardiopulmonary insufficiency, or contralateral vocal cord paralysis, according to the International Journal of Surgery 5
Caution should be exercised in pregnant or breastfeeding women, as recommended by the International Journal of Surgery 5